NCT06766253 The Effects of GMA-TULIP, I-gel, and BlockBuster Laryngeal Mask in Laparoscopic Surgeries With Trendelenburg Position Under General Anesthesia
| NCT ID | NCT06766253 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Second Affiliated Hospital of Chongqing Medical University |
| Condition | Sore-throat |
| Study Type | INTERVENTIONAL |
| Enrollment | 195 participants |
| Start Date | 2024-08-21 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 195 participants in total. It began in 2024-08-21 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to compare the application effects of traditional inflatable BlockBuster laryngeal mask, i-gel non-inflatable laryngeal mask and GMA-TULIP non-inflatable laryngeal mask in laparoscopic surgeries with trendelenburg position under general anesthesia, in order to explore which laryngeal mask is best for reducing postoperative throat pain of patients and improving patient comfort and satisfaction.
Eligibility Criteria
Inclusion Criteria: 1. Patients received laparoscopic surgeries with trendelenburg position and an estimated surgery duration of less than 3 hours. 2. Ages between 18 to 80, and body mass index less than 28 kg/m². 3. American Society of Anesthesiologists (ASA) Grades I-III. 4. Patients are willing to participate and be able to understand and sign an informed consent form. Exclusion Criteria: 1. Patients with a mouth opening less than 2 cm. 2. Patients with risk factors for regurgitation and aspiration of gastric contents. 3. Patients with laryngopharyngeal diseases. 4. Patients with potentially difficult airways. 5. Patients with hearing, intellectual, communication, and cognitive impairments. 6. Any reason that patients could not cooperate with the study or that the researcher deems inappropriate for inclusion in this trial.
Contact & Investigator
Bing Chen
PRINCIPAL INVESTIGATOR
The Second Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT06766253 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sore-throat. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06766253 currently recruiting?
Yes, NCT06766253 is actively recruiting participants. Contact the research team at chenbing@cqmu.edu.cn for enrollment information.
Where is the NCT06766253 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06766253 clinical trial?
NCT06766253 is sponsored by The Second Affiliated Hospital of Chongqing Medical University. The principal investigator is Bing Chen at The Second Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 195 participants.